I. Diaz Perez

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population

P. Mele, E. Podesta, A. Solano, 2018, Human Genomics.

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.

R. Dziadziuszko, A. Filippi, I. Diaz Perez, 2021, Future oncology.

108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

J. Mazières, A. Delmonte, M. Reck, 2022, Annals of Oncology.

BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population

P. Mele, E. Podesta, A. Solano, 2018, Human Genomics.